Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 8 | 9 |
| 2003 | 1 | 5 | 6 |
| 2004 | 2 | 9 | 11 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 8 | 13 |
| 2008 | 7 | 9 | 16 |
| 2009 | 5 | 4 | 9 |
| 2010 | 8 | 18 | 26 |
| 2011 | 3 | 11 | 14 |
| 2012 | 9 | 16 | 25 |
| 2013 | 10 | 13 | 23 |
| 2014 | 10 | 16 | 26 |
| 2015 | 7 | 17 | 24 |
| 2016 | 13 | 12 | 25 |
| 2017 | 13 | 20 | 33 |
| 2018 | 20 | 10 | 30 |
| 2019 | 14 | 19 | 33 |
| 2020 | 13 | 15 | 28 |
| 2021 | 12 | 10 | 22 |
| 2022 | 2 | 7 | 9 |
| 2023 | 5 | 5 | 10 |
| 2024 | 8 | 7 | 15 |
| 2025 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
3D genome organization shapes DNA damage susceptibility to platinum-based drugs. Nucleic Acids Res. 2025 May 22; 53(10).
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
-
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.
-
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
-
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31; 613:217505.
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):328-336.
-
Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer. J Exp Med. 2025 Jan 06; 222(1).